AI Biotech Valuation Modeling: Why the rNPV Spreadsheet Is No Longer Enough
Traditional rNPV models are underperforming for AI-discovered biotech assets because their probability of success benchmarks and competitive intelligence inputs do not reflect the speed at which AI pipelines and competitive landscapes change. AI valuation tools add continuous competitive monitoring, AI-calibrated PoS inputs, and rapid scenario generation. This article explains where the leverage points are and how to start.
AI Biotech Valuation Modeling: Why the rNPV Spreadsheet Is No Longer Enough Read More »